Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 22, 2023 17:02 ET | Source: Portnoy Law

FULCRUM THERAPEUTICS, INC.: Please contact the Portnoy Law Firm to recover your losses; June 27, 2023 deadline

LOS ANGELES, June 22, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC). investors that a lawsuit filed on behalf of...
June 12, 2023 19:22 ET | Source: Robbins LLP

Fulcrum Therapeutics, Inc. (FULC) Class Action: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Fulcrum Therapeutics, Inc. Class Action Case

SAN DIEGO, June 12, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Fulcrum Therapeutics, Inc....
May 23, 2023 18:26 ET | Source: Robbins LLP

Fulcrum Therapeutics, Inc. (FULC) Equity Alert: Contact Robbins LLP to Learn about the Fulcrum Therapeutics, Inc. Securities Fraud Class Action and Lead Plaintiff Deadline

SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Fulcrum Therapeutics, Inc....
May 15, 2023 17:27 ET | Source: Robbins LLP

Fulcrum Therapeutics, Inc. (FULC) Class Action Alert: Robbins LLP Urges Investors to Contact the Firm for Information about the Fulcrum Therapeutics, Inc. Securities Class Action

SAN DIEGO, May 15, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Fulcrum Therapeutics, Inc....
May 02, 2023 17:59 ET | Source: Robbins LLP

Fulcrum Therapeutics, Inc. (FULC) Shareholder Notice: Robbins LLP Reminds Investors of Class Action Against Fulcrum Therapeutics, Inc.

SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased Fulcrum Therapeutics, Inc....